Cargando…
Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial
CONTEXT: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis. OBJECTIVE: The effects of anatabine in patients with Hashimoto's thyroi...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Endocrine Society
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928963/ https://www.ncbi.nlm.nih.gov/pubmed/24178792 http://dx.doi.org/10.1210/jc.2013-2951 |
_version_ | 1782304335969910784 |
---|---|
author | Schmeltz, Lowell R. Blevins, Thomas C. Aronoff, Stephen L. Ozer, Kerem Leffert, Jonathan D. Goldberg, Marc A. Horowitz, Barry S. Bertenshaw, Richard H. Troya, Pedro Cohen, Amy E. Lanier, Ryan K. Wright, Curtis |
author_facet | Schmeltz, Lowell R. Blevins, Thomas C. Aronoff, Stephen L. Ozer, Kerem Leffert, Jonathan D. Goldberg, Marc A. Horowitz, Barry S. Bertenshaw, Richard H. Troya, Pedro Cohen, Amy E. Lanier, Ryan K. Wright, Curtis |
author_sort | Schmeltz, Lowell R. |
collection | PubMed |
description | CONTEXT: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis. OBJECTIVE: The effects of anatabine in patients with Hashimoto's thyroiditis were studied. DESIGN, SETTING, PATIENTS, AND INTERVENTION: This was a double-blind, randomized, placebo-controlled multisite study. A total of 146 patients (70 treated with anatabine and 76 with placebo) completed the study. Approximately 50% of patients in each group were taking levothyroxine. Anatabine lozenges (9–24 mg/d) or placebo, each containing vitamins A and D(3), were administered orally 3 times a day for 3 months. MAIN OUTCOME MEASURES: Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels were assessed. Safety was assessed through adverse events, clinical laboratory evaluations, and vital sign measurements. RESULTS: Anatabine-treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those receiving placebo (P = .027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb levels. Mean ± SD TgAb values decreased by 46.2 ± 101.1 and 3.9 ± 83.9 World Health Organization units for the anatabine and placebo groups, respectively. Significantly more patients had a >20% drop in TgAb levels in the anatabine than placebo group (P = .023). Overall, the anatabine supplement was safe and well tolerated, although significantly (P < .05) more patients in the anatabine group reported adverse events. CONCLUSIONS: These results demonstrate an immunological effect of anatabine on TgAb levels. Further studies are warranted to determine the longer-term effects and possible actions of anatabine on the course of Hashimoto's thyroiditis. |
format | Online Article Text |
id | pubmed-3928963 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | Endocrine Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-39289632014-02-26 Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial Schmeltz, Lowell R. Blevins, Thomas C. Aronoff, Stephen L. Ozer, Kerem Leffert, Jonathan D. Goldberg, Marc A. Horowitz, Barry S. Bertenshaw, Richard H. Troya, Pedro Cohen, Amy E. Lanier, Ryan K. Wright, Curtis J Clin Endocrinol Metab JCEM Online: Brief Reports CONTEXT: Hashimoto's thyroiditis is less prevalent in tobacco smokers. Anatabine, an alkaloid found in Solanaceae plants including tobacco, has been reported to ameliorate a mouse model of Hashimoto's thyroiditis. OBJECTIVE: The effects of anatabine in patients with Hashimoto's thyroiditis were studied. DESIGN, SETTING, PATIENTS, AND INTERVENTION: This was a double-blind, randomized, placebo-controlled multisite study. A total of 146 patients (70 treated with anatabine and 76 with placebo) completed the study. Approximately 50% of patients in each group were taking levothyroxine. Anatabine lozenges (9–24 mg/d) or placebo, each containing vitamins A and D(3), were administered orally 3 times a day for 3 months. MAIN OUTCOME MEASURES: Serum thyroperoxidase antibody (TPOAb) and thyroglobulin antibody (TgAb) levels were assessed. Safety was assessed through adverse events, clinical laboratory evaluations, and vital sign measurements. RESULTS: Anatabine-treated patients had a significant reduction in absolute serum TgAb levels from baseline by study end relative to those receiving placebo (P = .027); however, there were no significant changes or differences in treatment group means for TPOAb or TgAb levels. Mean ± SD TgAb values decreased by 46.2 ± 101.1 and 3.9 ± 83.9 World Health Organization units for the anatabine and placebo groups, respectively. Significantly more patients had a >20% drop in TgAb levels in the anatabine than placebo group (P = .023). Overall, the anatabine supplement was safe and well tolerated, although significantly (P < .05) more patients in the anatabine group reported adverse events. CONCLUSIONS: These results demonstrate an immunological effect of anatabine on TgAb levels. Further studies are warranted to determine the longer-term effects and possible actions of anatabine on the course of Hashimoto's thyroiditis. Endocrine Society 2014-01 2013-10-31 /pmc/articles/PMC3928963/ /pubmed/24178792 http://dx.doi.org/10.1210/jc.2013-2951 Text en Copyright © 2014 by The Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/us/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | JCEM Online: Brief Reports Schmeltz, Lowell R. Blevins, Thomas C. Aronoff, Stephen L. Ozer, Kerem Leffert, Jonathan D. Goldberg, Marc A. Horowitz, Barry S. Bertenshaw, Richard H. Troya, Pedro Cohen, Amy E. Lanier, Ryan K. Wright, Curtis Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title | Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title_full | Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title_fullStr | Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title_full_unstemmed | Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title_short | Anatabine Supplementation Decreases Thyroglobulin Antibodies in Patients With Chronic Lymphocytic Autoimmune (Hashimoto's) Thyroiditis: A Randomized Controlled Clinical Trial |
title_sort | anatabine supplementation decreases thyroglobulin antibodies in patients with chronic lymphocytic autoimmune (hashimoto's) thyroiditis: a randomized controlled clinical trial |
topic | JCEM Online: Brief Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3928963/ https://www.ncbi.nlm.nih.gov/pubmed/24178792 http://dx.doi.org/10.1210/jc.2013-2951 |
work_keys_str_mv | AT schmeltzlowellr anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT blevinsthomasc anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT aronoffstephenl anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT ozerkerem anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT leffertjonathand anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT goldbergmarca anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT horowitzbarrys anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT bertenshawrichardh anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT troyapedro anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT cohenamye anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT lanierryank anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial AT wrightcurtis anatabinesupplementationdecreasesthyroglobulinantibodiesinpatientswithchroniclymphocyticautoimmunehashimotosthyroiditisarandomizedcontrolledclinicaltrial |